title: Type 2 diabetes mellitus--current therapies and the emergence of surgical options.
abstract: Patients with type 2 diabetes mellitus (T2DM) are usually treated with pharmacologic agents in combination with lifestyle modification. The development of new antidiabetic agents, such as insulin analogs and incretin-based therapies, has led to treatment strategies that enable many patients with T2DM to achieve target HbA(1c) levels (≤7.0%). However, many factors-including those related to the patient or the health-care provider, drug inadequacies and adverse effects-can interfere with the ability of some patients to reach metabolic targets. Clinical data from the USA indicate that HbA(1c) concentration, blood pressure and serum levels of lipids in patients with T2DM are progressively decreasing toward the target goals set by the American Diabetes Association. These improvements in metabolic regulation have led to a 30-40% decrease in reported microvascular and macrovascular complications of diabetes mellitus in the USA. Gastric bypass surgery in morbidly obese individuals with T2DM leads to remission of the diabetes mellitus in the majority of patients and improvement in the rest. A major contributor to this improvement is an alteration in gastrointestinal hormone secretions. Interventional surgery might, therefore, be considered a reasonable therapeutic alternative for overweight and obese (BMI <35 kg/m²) patients with T2DM who do not respond to medical therapy.
authors.affiliation: State University of New York Health Science Center at Brooklyn, Department of Medicine, Brooklyn, New York, NY 11203, USA. hlebovitz1@hotmail.com
authors.forename: Harold E
authors.initials: HE
authors.lastname: Lebovitz
mesh_terms: D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000209:etiology / Q000601:surgery*; D015390:Gastric Bypass / Q000639:trends*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D009765:Obesity / Q000097:blood / Q000150:complications / Q000601:surgery; D016032:Randomized Controlled Trials as Topic / Q000639:trends; D040242:Risk Reduction Behavior; D016896:Treatment Outcome
chemical_list: D006442:Glycated Hemoglobin; C517652:hemoglobin A1c protein, human